PT Saptausaha Gemilangindah Tbk (SAGE)
Jul 31, 2025 - SAGE was delisted (reason: acquired by SUPN)
8.68
-0.02 (-0.23%)
Inactive · Last trade price on Jul 30, 2025
Sage Therapeutics Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for Sage Therapeutics stock had an average target of 9.37, with a low estimate of 4.00 and a high estimate of 26.
Price Target: $9.37 (+7.95%)
Analyst Consensus: Hold
* Price targets were last updated on Jul 8, 2025.
Analyst Ratings
The average analyst rating for Sage Therapeutics stock from 16 stock analysts was "Hold". This means that analysts believed this stock was likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 3 | 3 | 3 | 3 | 2 | 1 |
| Hold | 15 | 15 | 14 | 14 | 15 | 14 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 1 | 1 | 1 | 1 | 0 | 0 |
| Total | 20 | 20 | 19 | 19 | 18 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Buy → Hold Downgrades $12 → $9.2 | Buy → Hold | Downgrades | $12 → $9.2 | +5.99% | Jul 8, 2025 |
| Baird | Baird | Hold Maintains $7 → $9 | Hold | Maintains | $7 → $9 | +3.69% | Jun 20, 2025 |
| Piper Sandler | Piper Sandler | Buy → Hold Downgrades $9 → $8.5 | Buy → Hold | Downgrades | $9 → $8.5 | -2.07% | Jun 17, 2025 |
| Truist Securities | Truist Securities | Hold Maintains $8 → $9 | Hold | Maintains | $8 → $9 | +3.69% | Jun 17, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $12 | Hold | Reiterates | $12 | +38.25% | Jun 17, 2025 |
Financial Forecast
Revenue This Year
83.97M
from 41.24M
Increased by 103.60%
Revenue Next Year
120.02M
from 83.97M
Increased by 42.93%
EPS This Year
-3.67
from -6.59
EPS Next Year
-2.94
from -3.67
Financial currency is IDR. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 136.4M | 198.7M | |||
| Avg | 84.0M | 120.0M | |||
| Low | 61.7M | 78.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 230.7% | 136.6% | |||
| Avg | 103.6% | 42.9% | |||
| Low | 49.6% | -6.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.08 | -1.76 | |||
| Avg | -3.67 | -2.94 | |||
| Low | -3.90 | -3.85 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.